無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

消化器疾患の創薬パイプラインレビュー:2018年

Gastrointestinal Diseases Drug Development Pipeline Review, 2018

発行 GlobalData 商品コード 766014
出版日 ページ情報 英文 98 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.39円で換算しております。
Back to Top
消化器疾患の創薬パイプラインレビュー:2018年 Gastrointestinal Diseases Drug Development Pipeline Review, 2018
出版日: 2018年12月20日 ページ情報: 英文 98 Pages
概要

当レポートでは、消化器疾患のパイプライン情勢に関する概要を提供しており、開発中の治療薬および治療薬の開発に関わる主要企業に関する包括的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 消化器疾患の調査範囲
  • 消化器疾患:概要
  • 腸炎:概要
  • 胃炎:概要
  • 腹膜炎:概要

第3章 治療薬の開発

  • 消化器疾患
  • 腸炎
  • 胃炎
  • 腹膜炎

第4章 治療薬の評価

  • 消化器疾患
  • 腸炎
  • 胃炎
  • 腹膜炎

第5章 治療薬開発に関与する企業

  • 消化器疾患
  • 腸炎
  • 胃炎
  • 腹膜炎

第6章 休止プロジェクト

  • 消化器疾患
  • 腸炎
  • 胃炎
  • 腹膜炎

第7章 中止プロジェクト

  • 消化器疾患

第8章 製品開発のマイルストーン

  • 消化器疾患
  • 腸炎
  • 胃炎
  • 腹膜炎

第9章 付録

図表

List of Tables

  • Table 1: Number of Products under Development for Gastroenteritis 8
  • Table 2: Number of Products under Development by Companies, Gastroenteritis 9
  • Table 3: Number of Products under Development by Universities/Institutes, Gastroenteritis 10
  • Table 4: Products under Development by Companies, Gastroenteritis 11
  • Table 5: Products under Development by Universities/Institutes, Gastroenteritis 11
  • Table 6: Number of Products under Development for Enterocolitis 12
  • Table 7: Number of Products under Development by Companies, Enterocolitis 13
  • Table 8: Number of Products under Development by Universities/Institutes, Enterocolitis 14
  • Table 9: Products under Development by Companies, Enterocolitis 14
  • Table 10: Products under Development by Universities/Institutes, Enterocolitis 14
  • Table 11: Number of Products under Development for Gastritis 15
  • Table 12: Number of Products under Development by Companies, Gastritis 16
  • Table 13: Products under Development by Companies, Gastritis 17
  • Table 14: Number of Products under Development for Peritonitis 18
  • Table 15: Number of Products under Development by Companies, Peritonitis 19
  • Table 16: Products under Development by Companies, Peritonitis 20
  • Table 17: Number of Products by Stage and Target, Gastroenteritis 22
  • Table 18: Number of Products by Stage and Mechanism of Action, Gastroenteritis 23
  • Table 19: Number of Products by Stage and Route of Administration, Gastroenteritis 25
  • Table 20: Number of Products by Stage and Molecule Type, Gastroenteritis 26
  • Table 21: Number of Products by Stage and Target, Enterocolitis 28
  • Table 22: Number of Products by Stage and Mechanism of Action, Enterocolitis 29
  • Table 23: Number of Products by Stage and Route of Administration, Enterocolitis 30
  • Table 24: Number of Products by Stage and Molecule Type, Enterocolitis 32
  • Table 25: Number of Products by Stage and Target, Gastritis 33
  • Table 26: Number of Products by Stage and Mechanism of Action, Gastritis 35
  • Table 27: Number of Products by Stage and Route of Administration, Gastritis 36
  • Table 28: Number of Products by Stage and Molecule Type, Gastritis 38
  • Table 29: Number of Products by Stage and Target, Peritonitis 39
  • Table 30: Number of Products by Stage and Mechanism of Action, Peritonitis 41
  • Table 31: Number of Products by Stage and Route of Administration, Peritonitis 42
  • Table 32: Number of Products by Stage and Molecule Type, Peritonitis 44
  • Table 33: Gastroenteritis - Pipeline by Kyowa Hakko Kirin Co Ltd 45
  • Table 34: Gastroenteritis - Pipeline by Medicago Inc 46
  • Table 35: Gastroenteritis - Pipeline by Ology Bioservices Inc 46
  • Table 36: Gastroenteritis - Pipeline by RedHill Biopharma Ltd 47
  • Table 37: Gastroenteritis - Pipeline by Regeneron Pharmaceuticals Inc 47
  • Table 38: Gastroenteritis - Pipeline by Takeda Pharmaceutical Co Ltd 48
  • Table 39: Gastroenteritis - Pipeline by UMN Pharma Inc 49
  • Table 40: Gastroenteritis - Pipeline by Vaxart Inc 49
  • Table 41: Enterocolitis - Pipeline by Avexegen Therapeutics Inc 50
  • Table 42: Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB 50
  • Table 43: Enterocolitis - Pipeline by Leadiant Biosciences Inc 51
  • Table 44: Enterocolitis - Pipeline by ProMetic Life Sciences Inc 51
  • Table 45: Gastritis - Pipeline by BCWorld Pharm Co Ltd 52
  • Table 46: Gastritis - Pipeline by Daewon Pharm Co Ltd 53
  • Table 47: Gastritis - Pipeline by Daewoong Pharmaceutical Co Ltd 53
  • Table 48: Gastritis - Pipeline by Kyowa Hakko Kirin Co Ltd 54
  • Table 49: Gastritis - Pipeline by Recce Ltd 55
  • Table 50: Gastritis - Pipeline by RedHill Biopharma Ltd 55
  • Table 51: Gastritis - Pipeline by Sequella Inc 56
  • Table 52: Peritonitis - Pipeline by GlaxoSmithKline Plc 56
  • Table 53: Peritonitis - Pipeline by Nosopharm SAS 57
  • Table 54: Peritonitis - Pipeline by Oncodesign SA 57
  • Table 55: Peritonitis - Pipeline by SynAct Pharma AB 58
  • Table 56: Gastroenteritis - Dormant Projects 59
  • Table 57: Enterocolitis - Dormant Projects 59
  • Table 58: Gastritis - Dormant Projects 60
  • Table 59: Peritonitis - Dormant Projects 61
  • Table 60: Gastroenteritis - Discontinued Products 62

List of Figures

  • Figure 1: Number of Products under Development for Gastroenteritis 8
  • Figure 2: Number of Products under Development by Companies, Gastroenteritis 9
  • Figure 3: Number of Products under Development by Universities/Institutes, Gastroenteritis 10
  • Figure 4: Number of Products under Development for Enterocolitis 12
  • Figure 5: Number of Products under Development by Companies, Enterocolitis 13
  • Figure 6: Number of Products under Development for Gastritis 15
  • Figure 7: Number of Products under Development by Companies, Gastritis 16
  • Figure 8: Number of Products under Development for Peritonitis 18
  • Figure 9: Number of Products under Development by Companies, Peritonitis 19
  • Figure 10: Number of Products by Targets, Gastroenteritis 21
  • Figure 11: Number of Products by Stage and Targets, Gastroenteritis 21
  • Figure 12: Number of Products by Mechanism of Actions, Gastroenteritis 22
  • Figure 13: Number of Products by Stage and Mechanism of Actions, Gastroenteritis 23
  • Figure 14: Number of Products by Routes of Administration, Gastroenteritis 24
  • Figure 15: Number of Products by Stage and Routes of Administration, Gastroenteritis 24
  • Figure 16: Number of Products by Molecule Types, Gastroenteritis 25
  • Figure 17: Number of Products by Stage and Molecule Types, Gastroenteritis 26
  • Figure 18: Number of Products by Targets, Enterocolitis 27
  • Figure 19: Number of Products by Stage and Targets, Enterocolitis 27
  • Figure 20: Number of Products by Mechanism of Actions, Enterocolitis 28
  • Figure 21: Number of Products by Stage and Mechanism of Actions, Enterocolitis 29
  • Figure 22: Number of Products by Stage and Routes of Administration, Enterocolitis 30
  • Figure 23: Number of Products by Molecule Types, Enterocolitis 31
  • Figure 24: Number of Products by Stage and Molecule Types, Enterocolitis 31
  • Figure 25: Number of Products by Targets, Gastritis 32
  • Figure 26: Number of Products by Stage and Targets, Gastritis 33
  • Figure 27: Number of Products by Mechanism of Actions, Gastritis 34
  • Figure 28: Number of Products by Stage and Mechanism of Actions, Gastritis 34
  • Figure 29: Number of Products by Routes of Administration, Gastritis 35
  • Figure 30: Number of Products by Stage and Routes of Administration, Gastritis 36
  • Figure 31: Number of Products by Molecule Types, Gastritis 37
  • Figure 32: Number of Products by Stage and Molecule Types, Gastritis 37
  • Figure 33: Number of Products by Targets, Peritonitis 38
  • Figure 34: Number of Products by Stage and Targets, Peritonitis 39
  • Figure 35: Number of Products by Mechanism of Actions, Peritonitis 40
  • Figure 36: Number of Products by Stage and Mechanism of Actions, Peritonitis 40
  • Figure 37: Number of Products by Routes of Administration, Peritonitis 41
  • Figure 38: Number of Products by Stage and Routes of Administration, Peritonitis 42
  • Figure 39: Number of Products by Molecule Types, Peritonitis 43
  • Figure 40: Number of Products by Stage and Molecule Types, Peritonitis 43
目次
Product Code: GBIHC053IDB

Abstract

Summary

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. There are 12 products in development for this indication.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics. There are eight products in development for this indication.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma.

The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, histamine 2 (H2) antagonists and proton pump inhibitors. There are 11 products in development for this indication.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis is the result of an infection of the fluid in the peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from the digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics. There are seven products in development for this indication.

Molecular targets in development for gastrointestinal diseases include toll-like receptors, interleukin receptors and bacterial proteins. Companies operating in this pipeline space include Kyowa Hakko Kirin, RedHill Biopharma and GlaxoSmithKline.

This report "Gastrointestinal Diseases Drug Development Pipeline Review, 2018" provides an overview of the pipeline landscape for gastrointestinal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 5
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Gastrointestinal Diseases Report Coverage 6
  • 2.2 Gastroenteritis - Overview 6
  • 2.3 Enterocolitis - Overview 6
  • 2.4 Gastritis - Overview 6
  • 2.5 Peritonitis - Overview 6

3 Therapeutics Development 7

  • 3.1 Gastroenteritis 7
  • 3.2 Enterocolitis 11
  • 3.3 Gastritis 14
  • 3.4 Peritonitis 17

4 Therapeutics Assessment 20

  • 4.1 Gastroenteritis 20
  • 4.2 Enterocolitis 26
  • 4.3 Gastritis 31
  • 4.4 Peritonitis 37

5 Companies Involved in Therapeutics Development 44

  • 5.1 Gastroenteritis 44
  • 5.2 Enterocolitis 49
  • 5.3 Gastritis 51
  • 5.4 Peritonitis 55

6 Dormant Projects 58

  • 6.1 Gastroenteritis 58
  • 6.2 Enterocolitis 58
  • 6.3 Gastritis 59
  • 6.4 Peritonitis 60

7 Discontinued Products 61

  • 7.1 Gastroenteritis 61

8 Product Development Milestones 62

  • 8.1 Gastroenteritis 62
  • 8.2 Enterocolitis 78
  • 8.3 Gastritis 87
  • 8.4 Peritonitis 94

9 Appendix 96

  • 9.1 Methodology 96
  • 9.2 Coverage 96
  • 9.3 Secondary Research 96
  • 9.4 Primary Research 96
  • 9.5 Expert Panel Validation 96
  • 9.6 Contact Us 96
  • 9.7 Disclaimer 97
Back to Top